Australia-based Brandon Capital tops off sixth fund with $290M

Brandon Capital has closed its sixth fund at A$439 million, far above the A$350 million goal it had set and more than 75% larger than its A$250 million fifth vehicle.

Headquartered in Melbourne, the firm has already begun investing Brandon BioCatalyst Fund Six (BB6). Companies it has backed include radiopharma company Advancell Pty. Ltd., antibody-drug conjugate developer Myricx Pharma Ltd. and cancer play Catalym GmbH...